Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2010 (First Quarter of Fiscal 2011)
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for the early detection of chronic diseases. Products are sold to clinical laboratories and point-of-care providers (physicians' offices, drugstores) globally. Operations include manufacturing in Irvine, California, and Mexicali, Mexico.
Key Financial Metrics
| Metric | Q1 2011 (Aug 31, 2010) | Q1 2010 (Aug 31, 2009) |
|---|---|---|
| Net Sales | $1,177,712 | $1,148,521 |
| Gross Profit | $388,780 | $376,437 |
| Gross Margin | 33.0% | 32.8% |
| Operating Loss | $(12,230) | $4,719 (Income) |
| Net Loss | $(12,186) | $7,934 (Income) |
| Cash and Equivalents | $812,869 | $1,692,165 (End of Q1 2010) |
| Working Capital | $3,148,448 | $3,176,438 (May 31, 2010) |
| Total Debt | $69,459 | $80,499 (May 31, 2010) |
| Operating Cash Flow | $(199,153) | $34,670 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 2.5% ($29,191) compared to the prior year quarter, primarily driven by increased sales to a domestic chain drug store.
- Profitability Decline: The company shifted from a net income of $7,934 in Q1 2010 to a net loss of $12,186 in Q1 2011. Operating expenses increased by $29,292, outpacing the increase in gross profit.
- Cost of Sales: Cost of sales as a percentage of revenue was 67.0% (down from 67.2%). This improvement was partially offset by a $56,458 sales incentive paid in free product to a major customer. Without this incentive, the cost of sales would have been approximately 62.2%.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 7.0% due to trade show costs and rent. Research and development (R&D) expenses increased 10.8% due to costs associated with integrating newly licensed products.
- Cash Flow: Operating cash flow turned negative, using $199,153 compared to providing $34,670 in the prior year. This was largely due to an $85,757 increase in inventory and the paydown of $84,629 in payables and accrued expenses.
Guidance, Outlook, and Risks
- Strategic Shift: Management eliminated its dedicated research department after the year-end to pursue a strategy of licensing technology from external institutions rather than internal development.
- Liquidity: The company maintains a $400,000 line of credit with Union Bank of California, which had a zero balance as of August 31, 2010. An equipment loan of approximately $69,500 remains outstanding.
- Forward-Looking Statements: The filing contains no specific numerical guidance for future periods. Management cautions that results may differ materially due to macroeconomic downturns, regulatory approvals, competition, and raw material availability.
- Risk Factors: Key risks include dependence on international distributors, potential border shutdowns affecting manufacturing/shipping, and the need to maintain NASDAQ listing requirements.
Investor Verification Checklist
- Sales Incentive Impact: Verify the sustainability of the $56,458 free product incentive and its effect on future gross margins.
- Inventory Build-up: Assess the $85,757 increase in inventory levels to ensure it aligns with demand and does not indicate obsolescence risks.
- Operating Cash Flow: Monitor the reversal of positive operating cash flow to a negative $199,153 and the company's ability to fund operations without external capital.
- R&D Strategy: Confirm the progress and costs associated with the new strategy of licensing external technology following the elimination of the internal R&D department.
- Debt Covenants: Review the terms of the $400,000 line of credit and the equipment loan to ensure compliance with covenants, particularly regarding maintaining a zero balance on the line of credit for 30 consecutive days annually.